Cumberland Pharmaceuticals Inc. (CPIX)
USD 4.07
(0.87%)
USD 4.07
(0.87%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 106.85 Thousand USD | -91.1% |
| 2022 | 1.2 Million USD | 110.94% |
| 2021 | -10.98 Million USD | -43.03% |
| 2020 | -7.67 Million USD | -14.32% |
| 2019 | -6.71 Million USD | 15.41% |
| 2018 | -7.93 Million USD | 77.71% |
| 2017 | -35.61 Million USD | -17.11% |
| 2016 | -30.41 Million USD | 16.69% |
| 2015 | -36.5 Million USD | 8.44% |
| 2014 | -39.86 Million USD | 2.46% |
| 2013 | -40.86 Million USD | 18.24% |
| 2012 | -49.98 Million USD | 23.28% |
| 2011 | -65.16 Million USD | -12.17% |
| 2010 | -58.09 Million USD | 0.78% |
| 2009 | -58.54 Million USD | -1070.08% |
| 2008 | -5 Million USD | 25.75% |
| 2007 | -6.73 Million USD | -696.41% |
| 2006 | -846.11 Thousand USD | 83.9% |
| 2005 | -5.25 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 3.09 Million USD | 2799.2% |
| 2024 Q2 | 4.23 Million USD | 36.61% |
| 2023 Q4 | 106.85 Thousand USD | -22.76% |
| 2023 Q3 | 138.34 Thousand USD | -80.15% |
| 2023 Q1 | 4.39 Million USD | 265.76% |
| 2023 Q2 | 696.91 Thousand USD | -84.14% |
| 2023 FY | 106.85 Thousand USD | -91.1% |
| 2022 FY | 1.2 Million USD | 110.94% |
| 2022 Q1 | 3.52 Million USD | 132.08% |
| 2022 Q2 | 1.29 Million USD | -63.21% |
| 2022 Q3 | -1.61 Million USD | -224.4% |
| 2022 Q4 | 1.2 Million USD | 174.52% |
| 2021 FY | -10.98 Million USD | -43.03% |
| 2021 Q2 | -10.09 Million USD | -24.7% |
| 2021 Q4 | -10.98 Million USD | -15.35% |
| 2021 Q1 | -8.09 Million USD | -5.4% |
| 2021 Q3 | -9.51 Million USD | 5.66% |
| 2020 Q3 | -7.33 Million USD | 6.33% |
| 2020 Q4 | -7.67 Million USD | -4.73% |
| 2020 FY | -7.67 Million USD | -14.32% |
| 2020 Q1 | -5.75 Million USD | 14.36% |
| 2020 Q2 | -7.82 Million USD | -36.06% |
| 2019 FY | -6.71 Million USD | 15.41% |
| 2019 Q4 | -6.71 Million USD | 3.76% |
| 2019 Q2 | -951.18 Thousand USD | 79.36% |
| 2019 Q3 | -6.97 Million USD | -633.66% |
| 2019 Q1 | -4.6 Million USD | 41.94% |
| 2018 FY | -7.93 Million USD | 77.71% |
| 2018 Q1 | -23.26 Million USD | 34.68% |
| 2018 Q3 | -26.25 Million USD | -9.84% |
| 2018 Q4 | -7.93 Million USD | 69.77% |
| 2018 Q2 | -23.9 Million USD | -2.77% |
| 2017 FY | -35.61 Million USD | -17.11% |
| 2017 Q2 | -27.91 Million USD | 9.58% |
| 2017 Q1 | -30.87 Million USD | -1.53% |
| 2017 Q4 | -35.61 Million USD | -4.69% |
| 2017 Q3 | -34.01 Million USD | -21.86% |
| 2016 Q1 | -34.74 Million USD | 4.83% |
| 2016 FY | -30.41 Million USD | 16.69% |
| 2016 Q3 | -31.84 Million USD | 1.52% |
| 2016 Q2 | -32.33 Million USD | 6.92% |
| 2016 Q4 | -30.41 Million USD | 4.51% |
| 2015 Q2 | -37.24 Million USD | 4.62% |
| 2015 FY | -36.5 Million USD | 8.44% |
| 2015 Q4 | -36.5 Million USD | 0.31% |
| 2015 Q3 | -36.61 Million USD | 1.68% |
| 2015 Q1 | -39.04 Million USD | 2.06% |
| 2014 Q2 | -39.05 Million USD | -0.01% |
| 2014 Q1 | -39.04 Million USD | 4.46% |
| 2014 Q3 | -39.64 Million USD | -1.52% |
| 2014 FY | -39.86 Million USD | 2.46% |
| 2014 Q4 | -39.86 Million USD | -0.56% |
| 2013 Q2 | -43.8 Million USD | 6.5% |
| 2013 Q3 | -41.15 Million USD | 6.06% |
| 2013 Q4 | -40.86 Million USD | 0.68% |
| 2013 FY | -40.86 Million USD | 18.24% |
| 2013 Q1 | -46.84 Million USD | 6.28% |
| 2012 Q3 | -45.85 Million USD | 4.29% |
| 2012 Q4 | -49.98 Million USD | -9.01% |
| 2012 FY | -49.98 Million USD | 23.28% |
| 2012 Q1 | -49.08 Million USD | 25.34% |
| 2012 Q2 | -47.91 Million USD | 2.38% |
| 2011 Q2 | -63.4 Million USD | -7.73% |
| 2011 Q4 | -65.73 Million USD | 0.25% |
| 2011 Q3 | -65.9 Million USD | -3.95% |
| 2011 FY | -65.16 Million USD | -12.17% |
| 2011 Q1 | -58.85 Million USD | -0.21% |
| 2010 FY | -58.09 Million USD | 0.78% |
| 2010 Q2 | -57.49 Million USD | 1.24% |
| 2010 Q1 | -58.21 Million USD | 0.56% |
| 2010 Q3 | -57.46 Million USD | 0.05% |
| 2010 Q4 | -58.73 Million USD | -2.2% |
| 2009 Q1 | -2.81 Million USD | 43.81% |
| 2009 Q3 | -59.33 Million USD | -869.17% |
| 2009 Q2 | -6.12 Million USD | -117.73% |
| 2009 Q4 | -58.54 Million USD | 1.32% |
| 2009 FY | -58.54 Million USD | -1070.08% |
| 2008 Q4 | -5 Million USD | 37.16% |
| 2008 Q3 | -7.96 Million USD | -19.6% |
| 2008 Q1 | -8.29 Million USD | -23.09% |
| 2008 Q2 | -6.65 Million USD | 19.74% |
| 2008 FY | -5 Million USD | 25.75% |
| 2007 Q3 | -4.63 Million USD | -3.26% |
| 2007 FY | -6.73 Million USD | -696.41% |
| 2007 Q2 | -4.48 Million USD | -10.78% |
| 2007 Q1 | -4.04 Million USD | -378.48% |
| 2007 Q4 | -6.73 Million USD | -45.5% |
| 2006 Q4 | -846.11 Thousand USD | 0.0% |
| 2006 FY | -846.11 Thousand USD | 83.9% |
| 2005 FY | -5.25 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 94.198% |
| Alpha Teknova, Inc. | 1.97 Million USD | 94.587% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 99.887% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 99.857% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 99.975% |
| Cosmos Health Inc. | 8.59 Million USD | 98.756% |
| Journey Medical Corporation | -9.7 Million USD | 101.101% |
| Embecta Corp. | 1.31 Billion USD | 99.992% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 99.977% |
| Dynavax Technologies Corporation | 106.63 Million USD | 99.9% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 100.082% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 99.975% |
| PainReform Ltd. | -7.95 Million USD | 101.344% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 100.683% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 100.683% |
| SCYNEXIS, Inc. | -19.35 Million USD | 100.552% |
| Safety Shot Inc | -2.28 Million USD | 104.678% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 101.133% |
| Procaps Group, S.A. | 242.93 Million USD | 99.956% |
| Theratechnologies Inc. | 24.87 Million USD | 99.57% |
| Harrow Health, Inc. | 116.41 Million USD | 99.908% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 104.24% |
| Biofrontera Inc. | 4.05 Million USD | 97.365% |
| DURECT Corporation | -7.65 Million USD | 101.396% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 100.319% |
| Cronos Group Inc. | -663.32 Million USD | 100.016% |
| OptiNose, Inc. | 58.06 Million USD | 99.816% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 99.983% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 100.733% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 102.061% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 99.288% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 101.68% |
| Radius Health, Inc. | 359.28 Million USD | 99.97% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 45.814% |
| ProPhase Labs, Inc. | 19.23 Million USD | 99.444% |
| Phibro Animal Health Corporation | 454.84 Million USD | 99.977% |
| Procaps Group S.A. | 242.93 Million USD | 99.956% |
| Alvotech | 1.06 Billion USD | 99.99% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 97.095% |
| Viatris Inc. | 17.13 Billion USD | 99.999% |
| Rockwell Medical, Inc. | 4.45 Million USD | 97.602% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 102.191% |
| SIGA Technologies, Inc. | -148.68 Million USD | 100.072% |
| Tilray Brands, Inc. | 158.97 Million USD | 99.933% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 99.912% |
| Shineco, Inc. | 29.29 Million USD | 99.635% |
| PetIQ, Inc. | 351.93 Million USD | 99.97% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 103.683% |
| Incannex Healthcare Limited | -5.48 Million USD | 101.948% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 99.94% |
| Alimera Sciences, Inc. | 55.3 Million USD | 99.807% |
| Silver Spike Investment Corp. | -32.61 Million USD | 100.328% |
| Assertio Holdings, Inc. | -32.52 Million USD | 100.329% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 107.178% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 102.112% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 102.22% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 101.301% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 97.466% |
| Hempacco Co., Inc. | 13.61 Million USD | 99.215% |
| Talphera, Inc. | -5.72 Million USD | 101.868% |
| Alvotech | 1.06 Billion USD | 99.99% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 98.504% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 100.11% |
| Currenc Group, Inc. | -16.57 Million USD | 100.645% |
| Kamada Ltd. | -46.43 Million USD | 100.23% |
| Indivior PLC | -33.95 Million USD | 100.315% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 58.991% |
| Flora Growth Corp. | -713 Thousand USD | 114.987% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 101.301% |
| Evolus, Inc. | 63.7 Million USD | 99.832% |
| HUTCHMED (China) Limited | -197.45 Million USD | 100.054% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 99.978% |
| Akanda Corp. | 3.9 Million USD | 97.263% |